Evoke Pharma Management
Management criteria checks 2/4
Evoke Pharma's CEO is Matt D'Onofrio, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is $857.37K, comprised of 52.5% salary and 47.5% bonuses, including company stock and options. directly owns 0.08% of the company’s shares, worth $7.89K. The average tenure of the management team and the board of directors is 2.5 years and 17.5 years respectively.
Key information
Matt D'Onofrio
Chief executive officer
US$857.4k
Total compensation
| CEO salary percentage | 52.5% |
| CEO tenure | less than a year |
| CEO ownership | 0.08% |
| Management average tenure | 2.5yrs |
| Board average tenure | 17.5yrs |
Recent management updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$7m |
| Dec 31 2023 | US$857k | US$450k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$602k | US$417k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$1m | US$407k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$828k | US$387k | -US$13m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Jun 30 2020 | n/a | n/a | -US$12m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$852k | US$372k | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$831k | US$357k | -US$8m |
Compensation vs Market: Matt's total compensation ($USD857.37K) is above average for companies of similar size in the US market ($USD649.63K).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt D'Onofrio (54 yo)
less than a year
Tenure
US$857,371
Compensation
Mr. Matthew J. D'Onofrio, also known as Matt, MBA, had been the Chief Business Officer and Executive Vice President at Evoke Pharma, Inc. since 2010 until 2023. He served as Treasurer and Secretary since M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$857.37k | 0.080% $ 7.9k | |
| Chief Medical Officer | 11yrs | US$728.49k | 0.017% $ 1.7k | |
| Chief Financial Officer | less than a year | no data | 0.020% $ 2.0k | |
| Chief Commercial Officer - Gimoti (TM) | 4.3yrs | no data | no data |
2.5yrs
Average Tenure
54yo
Average Age
Experienced Management: EVOK's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$857.37k | 0.080% $ 7.9k | |
| Independent Director | 17.5yrs | US$77.54k | 0% $ 0 | |
| Independent Director | 17.5yrs | US$79.43k | 0.0014% $ 133.1 | |
| Independent Chairman of the Board | 17.5yrs | US$102.95k | 0.11% $ 11.1k | |
| Independent Director | 17.5yrs | US$79.18k | 0.0065% $ 638.8 | |
| Independent Director | 3.6yrs | US$85.31k | 0% $ 0 | |
| Director | less than a year | no data | no data |
17.5yrs
Average Tenure
62yo
Average Age
Experienced Board: EVOK's board of directors are seasoned and experienced ( 17.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 14:35 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evoke Pharma, Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Edward Woo | Ascendiant Capital Markets LLC |
| Difei Yang | Brean Capital |